Lv41
652 积分 2024-08-19 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
23天前
已完结
SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial
1个月前
已完结
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
1个月前
已完结
MA03.02 TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors
1个月前
已完结
Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter study
1个月前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
1个月前
已完结
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
1个月前
已完结
Optimizing adjuvant therapy under the guidance of MPR: A multicenter retrospective analysis of neoadjuvant therapy in non-small cell lung cancer
2个月前
已完结
Optimizing adjuvant therapy under the guidance of MPR: A multicenter retrospective analysis of neoadjuvant therapy in non-small cell lung cancer
2个月前
已关闭
STELLAR-303: Breaking the immunotherapy wall in MSS colorectal cancer
2个月前
已完结
皖公网安备34019202002308
